Neonatal stroke is a major cause of mortality and long-term morbidity in infants and children. Currently, very limited therapeutic strategies are available to protect the developing brain against ischemic damage and promote brain repairs for pediatric patients. Moreover, children who experienced neonatal stroke often have developmental social behavior problems. Cellular using bone marrow mesenchymal stem cells (BMSCs) has emerged as a regenerative after stroke.
Human aging is associated with a vast array of clinical disorders that all relate to the body’s inability to maintain homeostasis. In our bodies, the healing process requires tight control of the acute inflammatory response. When the levels of inflammatory markers such as interleukin-6, tumor necrosis factor alpha, and C-reactive protein are elevated, there is a direct correlation with several chronic diseases of aging such as cardiovascular disease,
Autologous bone marrow-derived mononuclear cells (MNCs) are a potential for ischemic stroke. However, the effect of MNCs in intracerebral hemorrhage (ICH) has not been fully studied. In this study, we investigated the effects of autologous MNCs in experimental ICH. ICH was induced by infusion of autologous blood into the left striatum in young and aged male Long Evans rats.
Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia, which induces neuron, kidney and eye dysfunction. Hyperglycemia is also a risk factor for dementia. T2DM also causes brain insulin resistance, oxidative stress and cognitive impairment. Futhermore, oxidative stress causes a complex dysregulation of cell metabolism resulting in insulin resistance and beta cell dysfunction. Alzheimer’s Disease (AD) is the most common form of dementia among older people worldwide,
Cell in neurological disability after traumatic brain injury (TBI) is in its initial clinical stage. We describe our preliminary clinical experience with three patients with diffuse axonal injury (DAI) who were treated with intrathecal administration of autologous mesenchymal stromal cells (MSCs).
Three patients with established neurological sequelae due to DAI received intrathecally autologous MSCs.
Background and Purpose—Preclinical data suggest that cell-based therapies have the potential to improve stroke outcomes.
Methods—Eighteen patients with stable, chronic stroke were enrolled in a 2-year, open-label, single-arm study to evaluate the safety and clinical outcomes of surgical transplantation of modified bone marrow–derived mesenchymal stem cells (SB623).
This study sought to evaluate the feasibility and safety of autologous bone marrow–derived and cardiogenically oriented mesenchymal stem cell and to probe for signs of efficacy in patients with chronic heart failure.
In pre-clinical heart failure models, cardiopoietic stem cell improves left ventricular function and blunts pathological remodeling.
The C-CURE (Cardiopoietic stem Cell in heart failURE) trial,
A promising approach to the results of chronic ischaemic heart disease (IHD) and heart failure is the use of stem cells. The last decade has seen a plethora of randomised controlled trials (RCTs) developed worldwide which have generated conflicting results.
The critical evaluation of clinical evidence on the safety and efficacy of autologous adult bone marrow-derived stem cells (BMSC) as a results for chronic ischaemic heart disease (IHD) and heart failure.
Stem cell offers potential in the regeneration of craniofacial bone defects; however, it has not been studied clinically. Tissue repair cells (TRCs) isolated from bone marrow represent a mixed stem and progenitor population enriched in CD90- and CD14-positive cells. In this phase I/II, randomized, controlled feasibility trial, we investigated TRC cell to reconstruct localized craniofacial bone defects.
Acute traumatic spinal cord injury (SCI) is marked by the enhanced production of local cytokines and pro-inflammatory substances that induce gliosis and prevent reinnervation. The transplantation of stem cells is a promising results strategy for SCI. In order to facilitate functional recovery, we employed stem cell alone or in combination with curcumin, a naturally-occurring anti-inflammatory component of turmeric (Curcuma longa),